Title : A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease - Herrmann_2016_J.Am.Med.Dir.Assoc_17_142 |
Author(s) : Herrmann N , O'Regan J , Ruthirakuhan M , Kiss A , Eryavec G , Williams E , Lanctot KL |
Ref : J Am Med Dir Assoc , 17 :142 , 2016 |
Abstract :
OBJECTIVES: Cholinesterase inhibitors (ChEIs) offer modest benefits in Alzheimer disease (AD), which must be balanced against risks. Relatively few data delineate the benefits and risks of long-term ChEI administration in institutionalized patients with advanced AD. This study investigated the effects of ChEI discontinuation in institutionalized patients with AD. DESIGN: Institutionalized patients with moderate to severe AD (standardized Mini- Mental Status Examination <=15) and treated with a ChEI for >/=2 years were randomized, double-blind, to ChEI continuation or placebo, with a 2-week tapering phase, for 8-weeks. MEASUREMENTS: The primary outcome of this pilot study was change on the Clinician's Global Impression of Change (CGI-C) scale. Secondary outcomes included safety, efficacy, and tolerability. Baseline (BL) predictors of clinical deterioration were also determined. |
PubMedSearch : Herrmann_2016_J.Am.Med.Dir.Assoc_17_142 |
PubMedID: 26482056 |
Herrmann N, O'Regan J, Ruthirakuhan M, Kiss A, Eryavec G, Williams E, Lanctot KL (2016)
A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease
J Am Med Dir Assoc
17 :142
Herrmann N, O'Regan J, Ruthirakuhan M, Kiss A, Eryavec G, Williams E, Lanctot KL (2016)
J Am Med Dir Assoc
17 :142